Core Viewpoint - The company, Kunming Pharmaceutical Group (600422.SH), reported a significant decline in both revenue and net profit for the fiscal year 2025, indicating challenges in its sales performance and profitability [1] Financial Performance - The company achieved a total revenue of approximately 6.577 billion yuan, representing a year-on-year decrease of 21.72% [1] - The estimated net profit attributable to shareholders is around 350 million yuan, reflecting a year-on-year decline of 46% [1] Sales and Profitability - The sales scale and gross profit margin of the company's products have both decreased compared to the previous year [1] Non-Recurring Gains - The company expects non-recurring gains to be approximately 243 million yuan, which is an increase of 6.1% year-on-year [1] - This increase is primarily driven by the listing of its associate company, Nanjing Weili Zhizhi Biotechnology Co., Ltd., on the Hong Kong Stock Exchange, leading to significant growth in the fair value changes and investment income of related financial assets, estimated at 119 million yuan [1] - Government subsidies included in the current period's profit are about 70 million yuan, which is a decrease of 24.15% year-on-year [1]